Multicenter Prospective Study Protocol for the Treatment of Rheumatoid Arthritis-Associated Pulmonary Fibrosis with Tocilizumab Combined with Tripterygium Glycosides Multicenter Prospective Study Protocol for the Treatment of Rheumatoid Arthritis-Associated Pulmonary Fibrosis with Tocilizumab Combined with Tripterygium Glycosides

INTERVENTION: Tocilizumab + Tripterygium glycosides:1.Tocilizumab: 8mg/kg by intravenous drip, every 4 weeks. Dilute to 100ml with 0.9%NS and drip for 1 hour. 2. Tripterygium glycosides: 20mg (2 tablets) orally, three times a day, taken after meals.;Tocilizumab:Tocilizumab: 8mg/kg by intravenous drip, every 4 weeks. Dilute to 100ml with 0.9%NS and drip for 1 hour.; CONDITION: Rheumatoid arthritis PRIMARY OUTCOME: High‐Resolution Computed Tomography; SECONDARY OUTCOME: Diffusing Capacity for Carbon Monoxide;American College of Rheumatology 20;Forced Vital Capacity;Functional Assessment of Chronic Illness Therapy‐Fatigue;Health Assessment Questionnaire‐Disability Index; INCLUSION CRITERIA: (1) Age: 18‐75 years old, gender not limited; (2) Conform to the 2010 ACR/EULAR RA classification criteria, with a disease course of =6 months; (3) Pulmonary fibrosis confirmed by HRCT (predicted FVC% 40‐80%, predicted DLCO% 30‐79%); (4) DAS28‐ESR >=3.2; (5) Having failed or been intolerant to at least one DMARDs treatment in the past; (6) The patient was clearly diagnosed with RA combined with ILD, and ILD caused by systemic sclerosis (scleroderma), dermatomyositis, systemic lupus erythematosus, Sjogren's syndrome, etc. was excluded. (7) A woman of childbearing age has a negative pregnancy test and agrees to contraception; (8) Voluntarily sign the informed consent form.